A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-09-08
AEs
3
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-28 (study day 34); relationship: Y; serious criteria: hospitalization
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-12-23 (study day 90); relationship: not assessed
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-01-04 (study day 102); relationship: Y
Data queries
No data queries.